Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra Inc’s Chief Accounting Officer Lambert Shiu reported a routine tax-related share disposition. On March 15, 2026, 150 shares of common stock were withheld by the company at $336.18 per share to satisfy tax obligations from vesting restricted stock units. After this tax-withholding transaction, Shiu directly owns 39,323 shares of Penumbra common stock and indirectly holds 300 shares through a spouse’s IRA.
Penumbra Inc’s chief financial officer, Maggie Yuen, sold 2,432 shares of common stock in an open-market transaction at $342.30 per share. The sale was carried out under her Rule 10b5-1 trading plan, which pre-arranges trades. After this transaction, she directly owns 18,353 shares, and a portion of these shares is subject to vesting.
Boston Scientific discussed the strategic rationale and integration approach for its proposed acquisition of Penumbra during a TD Cowen conference Q&A on March 3, 2026. Executives said Penumbra would operate as a stand-alone global business unit within Boston Scientific’s cardiovascular/ICTx portfolio, retaining its commercial team and leadership. Management highlighted opportunities to scale Penumbra outside the U.S., leverage Boston Scientific’s supply chain (including Costa Rica manufacturing), and cross-sell complementary products across neurovascular, thrombectomy, vascular and interventional cardiology accounts. The transaction remains subject to regulatory review and customary closing conditions; Boston Scientific referenced a Form S-4/proxy filing in connection with the proposed transaction.
PEN: Morgan Stanley Smith Barney LLC filed a Form 144 reporting proposed sales of Common stock. The filing lists 900 shares sold as Exercised Shares on 03/05/2025, 1,112 Restricted Stock dated 12/16/2020, and 420 shares from an Employee Stock Purchase Plan dated 11/19/2021.
Penumbra, Inc. reports strong 2025 growth and outlines a planned sale to Boston Scientific. Revenue reached $1,403.7 million, up 17.5% from 2024, driven by thrombectomy products at $947.9 million and embolization/access at $455.7 million. Income from operations rose to $189.2 million, rebounding from 2024 when a $115.3 million impairment tied to exiting the immersive healthcare business depressed results. The company has agreed to a merger valuing it at about $14.5 billion, with shareholders able to elect $374 in cash or 3.8721 Boston Scientific shares per Penumbra share, subject to an overall mix of roughly 73% cash and 27% stock. As of February 4, 2026, Penumbra had 39,243,053 common shares outstanding. The filing also details large addressable markets in thrombectomy and embolization, an expanding global manufacturing and sales footprint, and extensive regulatory and intellectual property protections, while highlighting risks around competition, reimbursement, regulation and execution of the proposed merger.
Penumbra, Inc. reported strong growth for the fourth quarter and full year 2025, highlighted by rising revenue and improved profitability. Fourth quarter revenue reached $385.4 million, up 22.1% from a year earlier, with net income of $47.3 million and an adjusted EBITDA margin of 20.5%.
For 2025, revenue grew to $1,403.7 million, an increase of 17.5%, while net income climbed to $177.7 million, or $4.52 per diluted share, and adjusted EBITDA was $266.8 million with a 19.0% margin. Thrombectomy and embolization products both delivered double-digit growth. Because of the proposed acquisition of Penumbra by Boston Scientific Corporation, the company is not providing 2026 guidance and will not host a conference call.
Grewal Harpreet reported acquisition or exercise transactions in this Form 4 filing.
Penumbra director Harpreet Grewal received a grant of 589 shares of common stock in the form of restricted stock units at no cost. The RSUs vest in four equal parts on March 31, June 30, September 30 and December 31 2026, if he continues serving as a director.
If the closing of the previously signed merger with Boston Scientific Corporation and Pinehurst Merger Sub, Inc. occurs, any unvested RSUs will fully vest at that closing, again subject to his continued service. After this award, he directly holds 8,819 Penumbra shares, with a portion still subject to vesting.
Penumbra Inc director Arani Bose reported an equity award and updated share holdings. On February 13, 2026, Dr. Bose acquired 589 shares of common stock through a grant or award with a price of $0.00 per share, bringing his directly held total to 1,147 shares.
Footnotes explain these are restricted stock units vesting in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, subject to his continued board service. Any unvested units will fully vest if the merger closing described in the cited Agreement and Plan of Merger occurs while he remains a director. The filing also notes 258,462 shares of common stock are held indirectly through Bose Family Holdings II, LLC.
Leeds Janet reported acquisition or exercise transactions in this Form 4 filing.
Penumbra Inc director Janet Leeds received an equity grant of 589 shares of common stock in the form of restricted stock units (RSUs) at no cash cost. The award increases her directly held shares to 6,639.
The RSUs vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, as long as she continues serving as a director through each date. If the Closing of the referenced merger with Boston Scientific Corporation occurs, any RSUs still unvested at that time will fully vest at Closing, again conditioned on her continued board service.
O'Rourke Bridget reported acquisition or exercise transactions in this Form 4 filing.
Penumbra director Bridget O'Rourke reported an equity award of 589 shares of common stock in the form of restricted stock units (RSUs). The award was granted at no cash cost and increased her directly held common stock to 5,962 shares after the transaction.
The RSUs vest in four equal installments on March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026, as long as she continues serving as a director through each date. If the Closing of the merger with Boston Scientific Corporation described in the merger agreement occurs, any unvested RSUs will fully vest at that Closing, subject to her continued board service through that date.